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Abstract 
 
Aim: Clarity on health expenditures is essential for the timely identification of risks that 
jeopardize the democratic provision of health services and the credibility of health insurance 
systems. Furthermore, observing health outcomes with geographical scope is essential for 
making multilateral associations. This study aimed at conveying information on the 
variability of important economic parameters of the health sector of Serbia and Greece from 
2007 to 2012, when the most serious financial crisis in the post-war economic history hit the 
global economy.  
Methods: Exchange rates, purchase-power-parities (PPP) and price indices were used for the 
bilateral review of health and pharmaceutical expenditure dynamics during 2007-2012. 
Prescription and dispensing changes were also studied taking into account the anatomical 
therapeutic chemical (ATC) structure of drugs consumed.  
Results: Greece was forced to cut down its total health care and pharmaceutical expenditure 
and mainly its out-of-pocket payments were more seriously affected by the recession. 
Surprisingly, emerging market of Serbia, although severely damaged by global recession, 
succeeded to maintain 19% growth of its per capita health expenditure and even 25% increase 
of its per capita spending on pharmaceuticals. Innovative pharmaceuticals showed an upward 
trend in both countries.  
Conclusions: These two countries might serve as an example of two distinct pathways of 
mature and emerging health care markets during financial constraints caused by global 
recession. Our findings show that producing disease-based feedback, in the long run, may 
empower the assessment of the return on investment on medical technology and healthcare 
systems’ cost-effectiveness.  
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Introduction 
Studying the cost of services in healthcare over multiple periods is a challenging task taking 
into account the coalescence of explicit and implicit parameters of change in the service 
products provided; namely, the changes in the commodities’ price and quality (1). 
Pharmaceutical care is, ‘par excellence’, a dynamic part of health sector. Firstly, 
pharmaceutical products are dominated by continual change due to the unstoppable 
technological improvement; secondly, the public sector has a role of payer and hence the 
power to regulate market prices. Financial fluctuations can thus act as tidal waves affecting 
providers, users and, ultimately, the population’s health. The following paragraphs attempt to 
delineate key changes in the Serbian and Greek healthcare sector covering the period from 
2007 onwards, when the global economy was hit by the most serious financial crisis in the 
post-war economic history (2).  
Serbia, the largest market of the Western Balkans region, has experienced bold growth of 
domestic public and private health care sector. Its total health expenditure grew from 7.7% of 
GDP in 2000 to 10.5% in 2009, well above the EU average. Its total public health 
expenditure increased enormously (from €1,175 million in 2004 to €1,847 million in 2012). 
At the same time, public spending on pharmaceuticals doubled, reaching a level of €742 
million (3). Unfortunately, like all the surrounding Balkan and Eastern European transitional 
post-socialist markets, the Serbian health system suffered heavily from several consecutive 
waves of global recession. After sustaining these impacts and introducing severe cost-cutting 
policies (some of which introduced only recently in 2014), the national market of Serbia 
began its slow recovery. 
The Greek health sector experienced a period of significant growth during the first decade of 
the millennium, with a total health expenditure rising from 8.7% of GDP in 2003 to 10% in 
2009, which was above the EU average (4). This growth was very pronounced particularly in 
the pharmaceutical sector where total expenditure more than doubled during the same period 
(from €3.2 billion in 2003 to €6.6 in 2009), rising from 1.9% to 2.8% of the GDP, with more 
than 78% being public expenditure (5). Specifically, public pharmaceutical expenditure 
increased by €0.5 billion per year between 2004 and 2009, reaching €5.2 billion in 2009 (4). 
Yet, following the signing of the Memorandum of Understanding (MoU) (6) in 2010, a series 
of extraordinary cost-containment measures and structural reforms were imposed on the 
Greek health sector, and on the pharmaceutical sector in particular, a sector regarded as a 
major contributor to both the deficit and the public debt due to the excessive public spending 
resulting from lack of control over both volume and cost of prescribing. Thus, since May 
2010, the pharmaceutical sector has been placed at the centre of fiscal consolidation, 
becoming one of the key areas of intervention in order to reduce public pharmaceutical 
expenditure to 1% of GDP, thereby approaching the European average (7). As a result, public 
pharmaceutical expenditure has dropped by 44% between 2009 and 2012, reaching €2.8 
billion and corresponding to 1.5% of the GDP in 2012 (IOBE, 2014).  
    
Methods 
 
Setting 
Serbian and Greek national pharmaceutical sectors assessments grounded in official data 
released by the respective national medicines’ agencies and national health insurance funds. 
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Study design consisted of a retrospective database analysis conducted from the First Party 
Payer’s perspective with a six-year long time horizon.  
Health outcomes regarding values, prices and the quality of the services provided were 
observed for Serbia and Greece. The time domain of the analysis covers the time interval 
2007-2012. Any information fissures caused by lack of data in health accounts are glossed 
over by more recent data. 
Differences in price levels between the two countries are measured with the official exchange 
rates into US dollars. The purchasing power parity (PPP) was additionally used as a real 
expenditure change survey tool (8). The presented PPPs are in 2011 US dollars (9). The price 
index of the comparative price level (CPL) was also computed according to the algebraic 
expression shown below (10): 
CPL =
RateExchange
PPP
 
 
The relevant outcomes are presented in Table 1. Other measures of bilateral comparability are 
also included in Table 1, such as the GDP and the GDP per capita which are based on PPPs in 
US dollars. Population magnitudes as the size of the population, the percentage of people 
aged 65 and over, and the crude birth and death rates per 1000 people are also appended.  
 
Table 1. Basic macroeconomic and demographic magnitudes in Serbia and Greece in 
2012/2013 
 
ECONOMY SERBIA GREECE 
Gross national income (PPP billions US$, 2012) 82.6 290.3 
Gross national income per capita (PPP US$, 2012) 11 430 26 170 
Indices   
PPP* (1 US$=1.000) 37.29 0.69 
Exchange rate (1 US$=1.000) 73.34 0.72 
CPL price index (US prices=100) 16.22 37.00 
Demographics   
Resident population (millions, 2013) 7.3 11.3 
Population ≥65 years (%, 2013) 14 20 
Crude death rate per 1000 people (2012) 14 11 
Crude birth rate per 1000 people (2012) 9 9 
Unemployment % of total labour force (2008-2012) 24 24 
 
* 
Sources: 2014 World Development Indicators. 2014 International Bank for Reconstruction and Development, The 
World Bank Purchasing Power Parities and the Real Size of World Economies. A Comprehensive Report of the 2011 
International Comparison Program. 2015 International Bank for Reconstruction and Development, The World Bank.  
 
 
Table 2 includes health expenditure values and changes based on PPPs. Annual percentage 
changes depicted in the last column of the table are yielded according to the harmonic mean 
of annual changes within the period 2007-2012.  
National total and pharmaceutical health expenditure per capita trends in Serbia and Greece 
during 2007-2012 are analytically presented (in PPP$ values) in Figure 1.  
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National health expenditures as percentage of GDP in Serbia and Greece during the period 
2007-2012 are also depicted in Figure 2.   
 
 
Table 2. Health expenditure values and their increase: Serbia and Greece, 2007-2012 
 
HEALTHCARE OUTCOME 2007 2012 Change (%) 
Annual 
change (%) 
Health expenditure per capita, PPP$ -  Serbia 1 047 1 250 19.39 3.44 
Health expenditure per capita, PPP$ - Greece 2 727 2 346 -13.95 -3.28 
Health expenditure, private (% of GDP) - Serbia 4 4 1.62 0.28 
Health expenditure, private (% of GDP) - Greece 4 3 -16.39 -3.88 
Health expenditure, private (% of total health 
expenditure -THE) - Serbia 
39 39 0.55 0.10 
Health expenditure, private (% of total health 
expenditure-THE) - Greece 
37 32 -11.53 -2.84 
Health expenditure, public (% of GDP) - Serbia 6 6 0.72 0.12 
Health expenditure, public (% of GDP) - Greece 6 6 7.09 1.06 
Health expenditure, public (% of government 
expenditure) - Serbia 
14 13 -3.37 -0.72 
Health expenditure, public (% of government 
expenditure)  - Greece 
12 11 -7.10 -1.56 
Health expenditure, public (% of total health 
expenditure) - Serbia 
61 61 -0.34 -0.07 
Health expenditure, public (% of total health 
expenditure) - Greece 
60 68 13.32 2.42 
Health expenditure, total (% of GDP)  -  Serbia 10 10 1.07 0.19 
Health expenditure, total (% of GDP)  -  Greece 10 9 -5.50 -1.20 
Health expenditure, total (current US$, millions) - 
Serbia 
4 035 4 030 -0.13 -1.00 
Health expenditure, total (current US$) - Greece 29 964 23 080 -22.97 -5.58 
Pharmaceutical expenditure per capita, PPP$ -  Serbia 305 382
*
 25.25 0.64 
Pharmaceutical expenditure per capita, PPP$ - Greece 676 673
*
 -0.44 -1.16 
 
* 
Sources: Data from database: Health Nutrition and Population Statistics. The World Bank. 2011. WHO Global 
Health Expenditure Database 2007–2012 and European Health for All Database (HFA-DB) 2007–2012. 
 
 
Tables 3 and 4 illustrate respectively the maximum and minimum absolute changes in the 
available outcomes of the two countries’ pharmaceutical sector, classified according to the 
ATC4 level of the anatomical therapeutic chemical classification system of drugs (11). 
Direct bilateral PPP comparisons were conducted for the GDP per capita and the 
pharmaceutical expenditure per capita, simplifying the Paasche price index. In the algebraic 
expression (2), Serbia is the base country and the PGS expresses Greece’s “p” values (i.e., the 
p.c. GDP or the p.c. pharmaceutical expenditure) in Serbian terms. “S” and “G” initials 
denote “Serbia” and “Greece”, respectively, and “q” is the general population of Greece. 
 
 
PGS = ΣpGqG / ΣpSqG 
(2) 
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Figure 1. National total and pharmaceutical health expenditure trends in Serbia and Greece 
during the period 2007-2012 (expressed in current PPP $ per capita) 
 
 
 
* 
Source: WHO Global Health Expenditure Database 2007-2012 and European Health for All Database (HFA-DB)  
   2007-2012. 
 
 
Figure 2. National health expenditure trends in Serbia and Greece during the period 2007-2012 
(expressed as a percentage of disposable Gross Domestic Product, GDP) 
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* 
Source: WHO Global Health Expenditure Database 2007-2012 and European Health for All Database (HFA-DB)    
  
 2007-2012. 
Table 3. Top 20 ATC drug classes based on turnover growth, 2007-2012 
 
ATC classes Serbia
*
 ATC classes Greece
†
 
C09BA ACE inhibitors  
and diuretics 
€ 2 246 511 L01XC Monoclonal antibodies € 11 287 179 
L01XC Monoclonal antibodies € 1 890 961 L01XE Protein kinase inhibitors € 9 001 287 
B01AC Platelet aggregation 
inhibitors excluding heparin 
€ 1 662 525 
L04AB Tumor necrosis factor 
alpha (TNF-α) inhibitors 
€ 8 711 090 
C10AA HMG CoA reductase 
inhibitors 
€ 1 560 979 
L04AA Selective 
immunosuppressants 
€ 4 954 700 
R03AK Adrenergics in 
combination with corticosteroids 
or other drugs, excl. 
Anticholinergics 
€ 1 430 330 
L02BX  Other hormone 
antagonists and related agents 
€ 4 405 048 
C09CA Angiotensin II 
antagonists, plain 
€ 1 180 464 
L04AX Other 
immunosuppressants 
€ 4 155 810 
L01XE Protein kinase inhibitors € 1 000 095 
S01LA Antineovascularisation 
agents 
€ 3 530 581 
A10AD Insulins and analogues 
for injection, intermediate- or 
long-acting combined with fast-
acting 
€ 863 908 L04AC Interleukin inhibitors € 2 756 671 
C07AB Beta blocking agents, 
selective 
€ 789 919 A16AB Enzymes € 2 440 854 
V08AB Water-soluble, 
nephrotropic, low osmolar X-ray 
contrast media 
€ 635 129 
J05AB Nucleosides and 
nucleotides excluding reverse 
transcriptase inhibitors 
€ 2 396 560 
N04BC Dopamine agonists € 600 260 
B03XA Other antianemic 
preparations 
€ 2 354 249 
G04CA Alpha-adrenoreceptor 
antagonists 
€ 589 965 C01EB Other cardiac preparations € 2 238 049 
J05AR Antivirals for treatment of 
HIV infections, combinations 
€ 581 846 
C09DX Angiotensin II antagonists, 
other combinations 
€ 2 001 835 
N02BE Anilides € 562 326 
A10BD Combinations of oral blood 
glucose lowering drugs 
€ 1 902 922 
C05BA Heparins or heparinoids 
for topical use 
€ 541 038 
R03DX Other systemic drugs for 
obstructive airway diseases 
€ 1 760 418 
L01CD Taxanes € 493 830 
L01XX Other antineoplastic 
agents 
€ 1 758 626 
N06DA Anticholinesterases € 438 968 B01AE Direct thrombin inhibitors € 1 606 684 
G04BE Drugs used in erectile 
dysfunction 
€ 432 442 L01BA Folic acid analogues € 1 597 243 
R01AA Sympathomimetics, plain € 418 995 L03AA Colony stimulating factors € 1 411 531 
A10BA Biguanides € 415 132 L01BC Pyrimidine analogues € 1 368 591 
 
*
 Sources: medicines and Medicinal Device Agency of Serbia annual reports on turnover and consumption of 
  
 pharmaceuticals; National Health Insurance Fund of Serbia.  
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†
Greek National Organisation for Health Care Services Provision-EOPYY.  
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Table 4. Bottom 20 ATC drug classes based on turnover growth 2007-2012 
 
ATC classes Serbia
*
 ATC classes Greece
†
 
C09AA ACE inhibitors, plain -€ 1 643 854 
C10AA HMG CoA 
reductase inhibitors 
-€ 31 679 014 
G03GA Gonadotropins -€ 1 330 919 
C09DA Angiotensin II 
antagonists and diuretics 
-€ 13 420 269 
J01FA Macrolides -€ 1 197 082 
B01AC Platelet 
aggregation inhibitors 
excluding heparin 
-€ 8 526 396 
J01DD Third-generation 
cephalosporins 
-€ 1 059 188 
C09CA Angiotensin II 
antagonists, plain 
-€ 7 929 987 
M01AB Acetic acid derivatives 
and related substances 
-€ 1 040 177 
N03AX Other 
antiepileptics 
-€ 7 071 604 
C01DA Organic nitrates -€ 935 780 
A02BC Proton pump 
inhibitors 
-€ 6 745 836 
A02BA H2-receptor antagonists -€ 896 631 
N06AB Selective 
serotonin reuptake 
inhibitors 
-€ 6 399 987 
M01AE Propionic acid 
derivatives 
-€ 846 670 
N06DA 
Anticholinesterases 
-€ 5 199 056 
J01DB First-generation 
cephalosporins 
-€ 691 096 
N05AX Other 
antipsychotics 
-€ 5 119 251 
L01CB Podophyllotoxin 
derivatives 
-€ 577 411 M05BA Bisphosphonates -€ 4 794 650 
B03XA Other antianemic 
preparations 
-€ 566 477 
C08CA Dihydropyridine 
derivatives 
-€ 4 165 272 
C04AD Purine derivatives -€ 563 692 
N06AX Other 
antidepressants 
-€ 3 810 668 
L04AA Selective 
immunosuppressants 
-€ 438 147 
C09AA ACE inhibitors, 
plain 
-€ 3 275 530 
J01CA Penicillins with 
extended spectrum 
-€ 433 257 
R03DC Leukotriene 
receptor antagonists 
-€ 3 182 560 
J01DC Second-generation 
cephalosporins 
-€ 417 805 
N05AH Diazepines, 
oxazepines, thiazepines 
and oxepines 
-€ 2 894 838 
B05BA Solutions for parenteral 
nutrition 
-€ 390 852 
A10BG 
Thiazolidinediones 
-€ 2 860 150 
R03AC Selective beta-2-
adrenoreceptor agonists 
-€ 376 303 R03BA Glucocorticoids -€ 2 455 708 
J01CR Combinations of 
penicillins, including beta-
lactamase inhibitors 
-€ 374 335 
C09BA ACE inhibitors 
and diuretics 
-€ 2 195 843 
R03DA Xanthines -€ 340 329 
A10BB Sulfonamides, 
urea derivatives 
-€ 2 137 085 
B05AA Blood substitutes and 
plasma protein fractions 
-€ 328 794 
L02BG Aromatase 
inhibitors 
-€ 2 007 464 
 
* Sources: medicines and Medicinal Device Agency of Serbia annual reports on turnover and consumption of 
   pharmaceuticals; National Health Insurance Fund of Serbia.  
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†
Greek National Organisation for Health Care Services Provision-EOPYY (estimations based on 2010-2012 data). 
Results 
Aside from minor differences in their aging populations, Serbia and Greece were spending 
similar amounts on health as percentage of the GDP, in the beginning of the recession. The 
recession, however, resulted in decreases in the amounts allocated for health in both 
countries, with Greece reducing mainly its private expenditure on health (from 37% to 32% 
of THE). In per capita terms, pharmaceutical expenditure recorded bold 25% growth in 
Serbia, whereas marginal decreases (0.4%) were jotted down for Greece, during the 
recession.  
Greece’s more intense recession effects on the pharmaceutical sector were also reflected on 
the values of the PGS price index. Greece’s p.c. GDP in PPP$ was 2.29 times the p.c. GDP of 
Serbia in 2012 (PGS = 26,170/11,430). Similarly, the pharmaceutical expenditure per capita of 
Greece was 2.22 times the pharmaceutical expenditure per capita of Serbia in 2007 (PGS = 
676/305), whereas in 2012 it reduced to 1.76 (PGS = 673/382). 
The pharmaceutical market internal structure of prescription and sales has in some cases 
moved in the same direction in the two countries. Specifically, within some therapeutic 
categories, pharmaceutical expenditure continued to grow despite the depression. These 
categories included the L01XC monoclonal antibodies, the L01XE protein-kinase inhibitors, 
the A10B blood glucose lowering drugs, excluding insulins and the J05A direct acting 
antiviral drugs. Continuing rise of share of innovative biological medicines is evident despite 
the financial constraints. 
Few important differences in adaptive responses to the economic crisis induced weaknesses 
were noticed between emerging and mature health market. While health expenditure per 
capita (PPP$) in Serbia still succeeded to grow for 19.4%, the Greek one felt almost 14% 
during these six years. The total health expenditure (THE) in Serbia decreased marginally by 
0.13%, whereas during the same time, the Greek THE fell abruptly by even 23%. Health 
expenditure percentage of GDP in Serbia grew 1% while Greek one decreased almost 5.5%. 
A similar pattern was noticed with private health care expenditure expressed either as 
percentage of THE or GDP: the Greek one decreased by 16.4% and 12% respectively, while 
Serbian private health expenditure recorded minor growth in crisis’ years. Governmental 
share of health expenditure has fallen dramatically in both countries although more 
prominently in Greece. Opposed to all the aforementioned recessional changes, public health 
expenditure was rising much faster in Greece compared to Serbia both on grounds of GDP 
proportion and THE proportion which reached 13.3% increase. At the same time, in Serbia, 
these values were slightly up and down, but only marginally (see Table 2). 
 
Discussion 
To date, all countries of the broader South Eastern Europe have found themselves in different 
stages of profound demographic transition outsourcing from increased longevity and falling 
fertility rates (12). Greece’s population is ageing faster considering its lower crude death rates 
and its higher proportion of old ages in the general population. Population aging in Serbia has 
deep historical roots and is likely to pose severe challenge on the national health system 
financing in the upcoming decades (13). This inevitable demographic change will be shaping 
growing needs for pharmaceuticals and the landscape of their consumption in both countries 
in the long run. 
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Observing much shorter time horizon of six recent years of global economic recession, 
emerging Serbian pharmaceutical market has undergone complex changes in terms of value-
based medicines prescription and dispensing. Regardless of significant difficulties and slower 
growth, national public expenditure on pharmaceuticals has doubled since 2004. Innovative 
cardiovascular, anti-diabetic agents, combined adrenergic and corticosteroid preparations and 
targeted immunotherapies dominated the landscape. Economic crisis induced package of 
policy measures provided temporary relief for the ongoing financial difficulties. 
Nevertheless, shortages of pharmaceuticals continued to occur more frequently compared to 
the period before 2008. These shortages occasionally refer even to the essential medicines 
and are primarily caused by the substantial public debt toward major multinational pharma 
companies supplying the Eastern European markets. Contemporary market access and 
reimbursement policies by regional authorities in most of Balkans peninsula limit patient 
access to the expensive innovative medicines to narrowly defined diagnoses related groups 
(14). It is essential to be aware of the boomerang effect created by these restrictive policies. 
Individuals, who are denied primary care preventive or screening services, ultimately end up 
in late severe stages of illness requiring expensive and complex inpatient treatment. A higher 
presence of clinically evolved conditions in transitional Eastern European countries has 
already been proven in the case of COPD (15), alcohol abuse (16) and cancer (17). These 
health system inefficiencies inherited from the socialist era create significant costs to the 
system, as well as worse health outcomes. High consumption of medicines indicated to treat 
some of key “prosperity” diseases such as diabetes (18), COPD, risky pregnancies (19,20), 
addiction disorders, hepatitis (21) and cancer (22) serves as the evidence of such 
vulnerabilities within the system (20). These major illnesses should also present core targets 
for more responsible, evidence-based national resource allocation strategies (23).  
In Greece, the pharmaceutical industry has traditionally represented an important sector of 
the economy and has been a major employer in the production, research and development, as 
well as distribution wholesale and retail. However, the Greek pharmaceutical market has been 
long characterized by significant overspending (24), with public pharmaceutical expenditure 
reaching unprecedented levels in 2009 and thus being blamed as one of the main contributors 
of public deficit and debt.  
Between 1990 and 2010, the applied pharmaceutical policy has focused mostly on price 
regulations in order to control expenditure, while no real effort was made to contain the 
volume of prescribed medicines, determined by the prescribing habits of physicians and by 
patients’ demand (25,26). As a result, public pharmaceutical expenditure continued to rise 
during this period, while the introduction of measures such as pharmaceutical pricing 
according to the lowest ex-factory European price and the positive list, had only a temporary 
effect on reducing expenditure, ultimately leading to the replacement of old products with 
new, more expensive ones and to the switching to more expensive medicines of the same 
therapeutic category (27,28). 
In light of the above and in the context of fiscal consolidation, a comprehensive health care 
reform was implemented after the signing of the MoU in 2010 and is still on-going, aiming, 
among other things, to reduce waste, control expenditure and increase the accountability and 
efficiency of the Greek pharmaceutical sector. The MoU defined a number of cost-
containment measures that had to be implemented within very tight timelines, targeting the 
reduction of both cost and volume of prescribed medicines. These measures included interim 
flat decreases of pharmaceutical prices, a new pharmaceutical pricing system according to 
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which prices are determined based on the average of the three lowest prices in the EU-27, 
introduction of positive, negative and over-the- counter (OTC) medication lists, reduction in 
the profit margins of pharmacists and wholesalers, collection of rebate and claw-back from 
pharmaceutical companies, changes in the distribution of high-cost medicines, increase in the 
use of generics in the national health system, introduction of electronic prescriptions for 
medicines, publication of clinical guidelines and prescribing protocols, as well as monitoring 
of physicians’ prescribing habits (29). 
Following the implementation of the MoU, the Greek government has primarily focused on 
applying cost-containment measures such as flat decreases of pharmaceutical prices and the 
collection of the rebates from pharmaceutical companies in order to achieve a fast reduction 
of pharmaceutical expenditure, while the measures and structural reforms aiming at the 
rationalization of the prescribing behaviour of physicians, such as e-prescribing and 
monitoring of physicians’ behaviour progressed at a slower pace. By 2012, public 
pharmaceutical expenditure shrunk by 44% since 2009, reaching 1.5% of GDP, while in 2013 
it was reduced to €2.4 billion (53% decrease). 
The recent changes in pharmaceutical policy which have been implemented in Greece in the 
context of its economic adjustment program have created turmoil in the pharmaceutical sector 
challenging its growth prospects and its long-term sustainability, thus resulting in instability 
in the market. This led to temporary drug shortages, hampering access to timely and effective 
therapy for the patients (30). At the same time, the policy of continuous reductions in 
pharmaceutical expenditure after a certain level and the substantial downsizing of the market, 
led to significant losses in public income resulting from the layoffs in the pharmaceutical 
sector and the subsequent lost of tax revenues and social contributions from pharmaceutical 
companies and pharmacies. The above demonstrate that even though in 2010 there was a real, 
urgent need for rationalization of the Greek pharmaceutical market and for the 
implementation of a number of structural reforms, currently, several years after the eruption 
of the fiscal crisis and while the health care reform is still on-going, there is a need to adopt a 
more multi-factorial approach in policy-making, i.e., an approach which will account for the 
potential impact of applied policies on: i) patient access; ii) insurance contributions, 
employment and GDP, as well as; iii) the benefits brought by the strengthening of scientific 
research and development, when estimating the net financial result of these policies. 
 
Conclusions 
These two countries might serve as an example of two distinct pathways of mature and 
emerging health care markets during financial constraints caused by global recession. Apart 
from the ostensible differences in their composition of health and pharmaceutical 
expenditure, Serbia and Greece both cut down on their pharmaceutical expenditure during the 
financial crisis, even though Greece was more seriously affected by the recession. 
Surprisingly, the emerging market of Serbia, although severely damaged by the global 
recession, succeeded to maintain 19% growth of its per capita health expenditure and even 
25% increase of its per capita spending on pharmaceuticals. 
The recession left unaffected certain pharmaceutical expenditure trends in both countries 
dictating inelastic areas in the curve of pharmaceutical needs. Specifically, an increasing 
expenditure was documented for the L01XC monoclonal antibodies, the L01XE protein-
kinase inhibitors, the A10B Blood glucose lowering drugs, excluding insulins and the J05A 
direct acting antiviral drugs.  
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The current results show that studies in the direction of producing disease-based feedback 
could empower the assessment of return on investment on medical technology, enhance the 
process of pharmaceutical expenditure estimations, predictions and projections and, in the 
long run, increase health outcomes’ predictability and the European healthcare systems’ cost-
effectiveness.  
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